Valproic Acid Improves Antisense-Mediated Exon-Skipping Efficacy in mdx Mice
Open Access
- 13 March 2025
- journal article
- research article
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 26 (6) , 2583
Abstract
Duchenne muscular dystrophy (DMD) is a severe genetic disorder characterized by the progressive degeneration of skeletal and cardiac muscles due to the absence of dystrophin. Exon-skipping therapy is among the most promising approaches for treating DMD, with several antisense oligonucleotides (ASO) already approved by the FDA; however, their limited efficacy highlights substantial potential for further improvement. In this study, we evaluate the potential of combining ASO with valproic acid (VPA) to enhance dystrophin expression and improve functional outcomes in a murine model of DMD. Our results indicate that the ASO+VPA treatment significantly increases dystrophin restoration across various muscle tissues, with particularly pronounced effects observed in cardiac muscle, where levels are nearly doubled compared to ASO monotherapy. Additionally, we demonstrate significant improvements in functional outcomes in treated mdx mice. Our findings suggest that the combined ASO+VPA therapy holds promise as an effective therapeutic approach to ameliorate muscle function in DMD, warranting further exploration of its mechanistic pathways and long-term benefits.Keywords
Funding Information
- Association Française contre les Myopathies (24114)
- Institut National de la Santé et la Recherche Médicale (INSERM) (24114)
- Association Monegasque contre les myopathies (AMM) (24114)
- Paris Ile-de-France Region and the Fondation UVSQ (24114)
This publication has 34 references indexed in Scilit:
- The unconditioned fear response in vertebrates deficient in dystrophinProgress in Neurobiology, 2024
- Histone deacetylase inhibitors improve antisense-mediated exon-skipping efficacy in mdx miceMolecular Therapy Nucleic Acids, 2022
- Valproic acid stimulates myogenesis in pluripotent stem cell-derived mesodermal progenitors in a NOTCH-dependent mannerCell Death & Disease, 2021
- Duchenne muscular dystrophyNature Reviews Disease Primers, 2021
- Safety, Tolerability, and Efficacy of Viltolarsen in Boys With Duchenne Muscular Dystrophy Amenable to Exon 53 SkippingJAMA Neurology, 2020
- An investigation on the effects of carbamazepine and sodium valproate on neuromuscular transmissionActa Neurologica Belgica, 2017
- Efficacy and Safety Profile of Tricyclo-DNA Antisense Oligonucleotides in Duchenne Muscular Dystrophy Mouse ModelMolecular Therapy Nucleic Acids, 2017
- Functional correction in mouse models of muscular dystrophy using exon-skipping tricyclo-DNA oligomersNature Medicine, 2015
- The use of urinary and kidney SILAM proteomics to monitor kidney response to high dose morpholino oligonucleotides in the mdx mouseToxicology Reports, 2015
- Functional and morphological recovery of dystrophic muscles in mice treated with deacetylase inhibitorsNature Medicine, 2006